Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XILLIX FDA APPROVED -- Ignore unavailable to you. Want to Upgrade?

To: Harry Stein who wrote (568)	3/28/2002 12:58:48 PM
From: Al Collard	Respond to of 572

Xillix Announces Clinical Investigator Agreement With Dr. Harvey Pass RICHMOND, BRITISH COLUMBIA--Xillix announced that Dr. Harvey Pass of Wayne State University/Karmanos Cancer Institute, Detroit, MI, has agreed to participate as a Clinical Investigator for the Onco-LIFE(TM) lung cancer clinical trial. Onco-LIFE is Xillix's latest device developed for the improved detection and localization of cancer in the lung and gastrointestinal (GI) tract. Xillix President and CEO, Ms. Cynthia Roney said, "We are delighted to have Dr. Pass participate in our Onco-LIFE lung cancer clinical trials. Dr. Pass is Professor of Surgery and Oncology at Wayne State University, and is Associate Director for Clinical Research at the Karmanos Cancer Institute, a National Cancer Institute Comprehensive Cancer Institute. While he was a Senior Investigator and Chief of Thoracic Oncology at the National Cancer Institute ("NCI") in Bethesda Maryland, Dr. Pass became recognized for clinical and benchwork studies in lung cancer and mesothelioma. He was one of the pioneers of the use of photodynamic therapy for lung cancer, and presently supervises a large, NCI funded lung cancer screening effort in Detroit which involves both the screening of sputum and the use of low dose helical CT scanning in collaboration with the International Early Lung Cancer Action Project. Dr. Pass has used Xillix's first-generation product, the Xillix LIFE-Lung System(TM) since 1998 both at Harper University Hospital and at the John A. Dingell Veterans Hospital of Detroit." Dr. Pass has published over 260 peer-reviewed papers in the literature. He is also the editor of the reference text: Lung Cancer: Principles and Practice published by Lippincott Williams and Wilkins. The Karmanos Cancer Institute is a unique, urban-based integrated system of research, patient care and education, dedicated to the prevention, early detection, treatment and eventual eradication of cancer. Research is at the core of care at the Karmanos Cancer Institute. Research programs are complemented by the Institute's academic affiliation with Wayne State University and its school of medicine - one of the largest medical schools in the US. The Institute also has a collaborative relationship with The Detroit Medical Center. More information on the Barbara Ann Karmanos Cancer Institute is available on its website at www.karmanos.org Xillix previously announced that Dr. Stephen Lam of the British Columbia Cancer Agency ("BCCA"), Vancouver, Canada will also participate as a Clinical Investigator as well as Medical Advisor for the Onco-LIFE lung cancer clinical trial planned for 2002. Additional Clinical Investigators will be announced as these arrangements are finalized. Xillix LIFE (TM) fluorescence-based medical imaging technology helps physicians diagnose early-stage lung and gastrointestinal ("GI") cancers. By exposing tissue to light from Xillix's patented fluorescence imaging device, physicians can detect pre-cancerous and cancerous cells. In 1996, clinical studies approved by the U.S. Food and Drug Administration ("FDA") confirmed that Xillix's first-generation lung device improved physicians' ability to detect lung cancer by 171% compared with conventional white light bronchoscopy alone. Xillix's latest device, Onco-LIFE(TM) is preparing for clinical trials to prove its value in detecting and localizing early lung and GI cancer. This new device leverages Xillix's worldwide experience and innovation. Onco-LIFE is compact, affordable, easy-to-use and incorporates both fluorescence and conventional imaging in a single system that will 'plug and play' with a wide range of endoscopic accessories to maximize global market acceptance.